NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, News, Headlines & Rumors

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its earnings results on Thursday, August, 9th. The biotechnology company reported $0.00 EPS for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.01. The biotechnology company earned $11.69 million during the quarter, compared to analysts' expectations of $13.46 million. Pieris Pharmaceuticals had a negative return on equity of 27.81% and a negative net margin of 22.38%. View Pieris Pharmaceuticals' Earnings History.

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Pieris Pharmaceuticals.

5 brokerages have issued 12 month price objectives for Pieris Pharmaceuticals' stock. Their predictions range from $12.00 to $13.00. On average, they expect Pieris Pharmaceuticals' share price to reach $12.3333 in the next year. This suggests a possible upside of 121.8% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

Some companies that are related to Pieris Pharmaceuticals include National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Protalex (PRTX), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI) and US Stem Cell (USRM).

Media headlines about PIRS stock have trended somewhat positive this week, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.84 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Pieris Pharmaceuticals.

Pieris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.97%), Acadian Asset Management LLC (3.94%), Aquilo Capital Management LLC (3.66%), Prosight Management LP (2.52%), American Century Companies Inc. (0.87%) and Wedge Capital Management L L P NC (0.50%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Trexquant Investment LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Aquilo Capital Management LLC, BlackRock Inc., Prosight Management LP, Acadian Asset Management LLC, American Century Companies Inc., GSA Capital Partners LLP, Spark Investment Management LLC and Assenagon Asset Management S.A.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $5.56.

Pieris Pharmaceuticals has a market capitalization of $306.92 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]